These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38610074)

  • 21. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    Frampton JE
    Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
    Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.
    Nargesi S; Dolatshahi Z; Rezapour A; Alipour V; Souresrafil A; Farabi H; Javadmoosavi SA; Safakhah M; Moradi N
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):543-554. PubMed ID: 34846235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
    Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
    Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
    Soo RA; de Marinis F; Han JY; Ho JC; Martin E; Servidio L; Sandelin M; Popat S
    Clin Lung Cancer; 2024 Jan; 25(1):80-84. PubMed ID: 37914594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to trametinib in a nonsmall cell lung cancer patient with osimertinib resistance harboring GNAS R201C and R201H mutations: a case report.
    Lv Y; Zhou C; Chen Z; Zhao X; Sun Y; Li J; Gong Z; Zhang D; Huang H
    Anticancer Drugs; 2022 Oct; 33(9):966-969. PubMed ID: 35946511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review.
    Liu J; Lei H; Zhang D; Zhang N
    Anticancer Drugs; 2024 Jul; 35(6):569-575. PubMed ID: 38527281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
    Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
    Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
    Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
    Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
    Lamb YN
    Target Oncol; 2021 Sep; 16(5):687-695. PubMed ID: 34564820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
    Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
    Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
    [No Abstract]   [Full Text] [Related]  

  • 35. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
    Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
    Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer 
with Epidermal Growth Factor Receptor Gene Mutation].
    Huang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):183-192. PubMed ID: 35340161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Bonanno L; Dómine M; Poole L; Bolanos A; Rukazenkov Y; Wu YL
    Target Oncol; 2024 Mar; 19(2):131-134. PubMed ID: 38466534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an
    Nishihara S; Yamaoka T; Ishikawa F; Ohmori T; Ando K; Kusumoto S; Kishino Y; Manabe R; Hasebe Y; Sagara H; Yoshida H; Tsurutani J
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
    Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
    Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.